Echocardiogram (ECG) measures that indicate the heart’s right ventricle (RV) and the pulmonary arteries are working poorly together to send blood to the lungs may help predict the presence of pulmonary hypertension (PH) in people with a certain type of heart failure, a recent publication indicates.
News
The U.S. Food and Drug Administration (FDA) has approved Cereno Scientific’s investigational drug CS1 in an extension of the ongoing Phase 2 clinical trial testing it in people with pulmonary arterial hypertension (PAH). This expanded access is sometimes called compassionate use. The…
A variant in the gene encoding the ALDH2 enzyme — fully known as aldehyde dehydrogenase 2 — was linked to an increased risk of pulmonary hypertension due to left heart disease (PH-LHD) among heart failure patients, a study in China found. Also called a polymorphism, meaning it involves one…
Note: This story was updated Jan. 30, 2024, to correct the approved indications of available treprostinil formulations. The U.S. Food and Drug Administration (FDA) has delayed its decision to extend the use of Yutrepia — Liquidia‘s inhaled dry powder formulation of treprostinil — to people with…
A protein known as MCJ might be a target of treatments needed to preserve heart function in people with pulmonary hypertension (PH), a study reports. Elevated levels of MCJ were found in the lung tissue of individuals affected by the low oxygen conditions of chronic obstructive pulmonary disease…
After a diagnosis of pulmonary arterial hypertension (PAH), rapidly starting treatment with a combination of therapies — both an endothelin receptor antagonist (ERA) and a phosphodiesterase type 5 inhibitor (PDE5i) — can lead to notable short-term improvements in heart health and physical function. That’s according to a new…
In people with pulmonary hypertension (PH), the endothelial cells that line the inside of blood vessels in the lungs take on features that are similar to what’s seen in some cancers, a new study found. The researchers who uncovered these features in these hard-to-access cells noted that they may…
Sensydia announced that it successfully completed a fifth study of its investigative Cardiac Performance System (CPS), intended to more easily and quickly detect pulmonary hypertension (PH) and heart failure than current approaches. CPS is a handheld and noninvasive device, powered by artificial intelligence, that uses heart sound…
Two genes were identified as potential drivers of pulmonary arterial hypertension (PAH) in a bioinformatics study, offering opportunities to better understand the disease and explore their use as biomarkers or therapeutic targets. The genes, called WDR43 and GNL2, were more active in the lungs of people with PAH than…
Four microRNAs (miRNAs) — small RNA molecules that regulate protein production — were found at different levels in blood samples from people with pulmonary hypertension (PH) compared with healthy people, a small study reported. Levels of two of these miRNAs were significantly higher in the PH patients versus the…
The first participant has entered ASCENT, a clinical study into the safety and tolerability of Liquidia’s Yutrepia, an inhaled dry powder formulation of treprostinil that is under regulatory review for pulmonary hypertension associated with interstitial lung disease (PH-ILD). The open-label study (NCT06129240) seeks to enroll an estimated…
While non-oral treatments for pulmonary arterial hypertension (PAH) can help ease symptoms, they can also make for poorer quality of life as they add new day-to-day challenges that go beyond those posed by the disease itself, a study found. The study, “Patients’ perspectives on the challenges associated with…
